Abstract 5383
Background
Cancer survivorship is increasing yet cancer treatment can cause de-conditioning and reduce physical capacity. Consequently there is a need to identify interventions which can improve health. This study investigated the impact of a personalised self-management programme on the physical and psychological health of cancer survivors with lifestyle related health risks.
Methods
For the purpose of this research the Moving on Programme was developed which is an intervention for cancer survivors to self-manage lifestyle. A randomised control pilot trial was conducted on 123 cancer survivors with a BMI > 25. Participants were randomly assigned to the control (n = 61) or intervention (n = 62) groups. The intervention group attended the Moving on Programme and engaged in personalised goal-setting to incrementally increase physical activity and made dietary changes. Participants in the control group received only brief standard advice. Objective measures of health behaviour were collected via Fitbit. Data on anthropometric, physiological, dietary behaviour and psychological measures were collected on all participants at baseline, three and six months. A sample of participants were interviewed (n = 13) to examine acceptability of the intervention.
Results
Overall, the results demonstrate a positive effect of the Moving on Programme. There was a significant reduction in BMI observed within the intervention group (p = 0.05) in the first three months. Positive participant outcomes also included improvement in physical and psychological wellbeing, and social functioning with reduced fatigue. Qualitative data demonstrated the acceptability of the intervention and participants identified that the Moving on Programme fulfils a deficit that exists in cancer survivorship and rehabilitation.
Conclusions
The Moving on Programme designed for this study, demonstrated physical and psychological benefits to participants. The use of behaviour change techniques and mobile technology was used effectively as an acceptable intervention that supports weight loss, promotes healthier behaviours and improves wellbeing in cancer survivors.
Clinical trial identification
ISRCTN18676721 https://doi.org/10.1186/ISRCTN18676721.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Irish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract